Antibodies
25 October 2024
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers24 October 2024
Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 202424 October 2024
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations22 October 2024
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies22 October 2024
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®21 October 2024
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers19 October 2024
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study19 October 2024
Astellas’ VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer17 October 2024
Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 for Infections Associated With Cystic Fibrosis17 October 2024
IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial “ACCELERATE Peanut” Evaluating IGNX001 in Peanut Allergy17 October 2024
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint17 October 2024
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-87815 October 2024
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 202415 October 2024
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study15 October 2024
IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with PfizerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports